aspirin + P2Y12 receptor inhibitor

A dual antiplatelet therapy (DAPT) regimen consisting of aspirin and a P2Y12 receptor inhibitor (such as clopidogrel, prasugrel, or ticagrelor). Aspirin acts by irreversibly inhibiting cyclooxygenase-1 (COX-1), which prevents the synthesis of thromboxane A2, a potent mediator of platelet aggregation. P2Y12 inhibitors block the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface, further inhibiting activation and aggregation. This combination is standard of care for preventing ischemic events and stent thrombosis following percutaneous coronary intervention (PCI). In the XIENCE 28 USA study, Abbott Medical Devices evaluated the safety of an abbreviated 1-month DAPT protocol (as short as 28 days) followed by aspirin monotherapy in patients at high bleeding risk (HBR) who received a XIENCE everolimus-eluting coronary stent.

Other names

Dual antiplatelet therapyDAPTaspirin + clopidogrelaspirin + prasugrelaspirin + ticagrelor